

Single nocturnal dose of an H₂ receptor antagonist for the treatment of duodenal ulcer

T GLEDHILL, O M HOWARD, MAXINE BUCK,
ANGELA PAUL, AND RICHARD H HUNT

From the Department of Gastroenterology, Royal Naval Hospital, Haslar, Gosport, Hants

SUMMARY Twenty four hour intragastric acidity and nocturnal acid output have been measured over five separate 24 hour periods in each of 12 patients with duodenal ulcer receiving either placebo, cimetidine 400 mg bd, cimetidine 300 mg nocte, ranitidine 150 mg bd, or ranitidine 300 mg nocte. In these doses ranitidine was significantly more effective at decreasing intragastric acidity and nocturnal acid output than cimetidine. There was no significant difference between twice daily ranitidine and night time ranitidine or between twice daily cimetidine and night time cimetidine in the reduction of intragastric acidity. Nocturnal acid output was controlled significantly better with ranitidine at night, twice daily dosage of ranitidine, and cimetidine at night, than by the twice daily dosage of cimetidine. It is suggested that a single nocturnal dose of cimetidine or ranitidine should be evaluated in a clinical trial.

Cimetidine was introduced in the United Kingdom for the treatment of duodenal ulcer with a recommended dose of 200 mg tds and 400 mg nocte (1 g/day).¹ More recently a dose of 400 mg bd has been shown to be equally effective at lowering intragastric acidity² and ulcer healing.³⁻⁴ Ranitidine is also recommended in a twice daily dose of 150 mg for ulcer healing⁵⁻⁶ and both of these drugs have been given effectively as a single night time dose to prevent ulcer relapse.⁷⁻⁸

Measures which decrease intragastric acidity over a 24 hour period are known to result in ulcer healing.⁹⁻¹⁰ Dragstedt suggested that nocturnal hypersecretion was the most important single factor in the pathogenesis of duodenal ulcer¹¹ and we have recently shown that although there is little variation in an individual's response to cimetidine during the daytime, overnight, patients who show a poor clinical response to cimetidine treatment also show little decrease in hydrogen ion (H⁺) activity.¹² These data and our knowledge that a single night time dose of an H₂ receptor antagonist can prevent duodenal ulcer relapse, suggest that a larger dose

may be effective primary treatment. During the daytime food partially buffers intragastric acidity and therefore a morning dose of drug may be unnecessary. To investigate this hypothesis, we have studied intragastric acidity over a 24 hour period comparing twice daily ranitidine with twice daily cimetidine and both drugs given as a single large bedtime dose.

Methods

PATIENTS

Twelve patients with an endoscopically proven duodenal ulcer in remission were each studied over five separate 24 hour periods receiving either placebo, cimetidine 400 mg bd, ranitidine 150 mg bd, cimetidine 800 mg nocte, or ranitidine 300 mg nocte. Treatments were randomised, taken single blind and administered at 2100 on the day before the study and at 0900 and 2100 on the study day for the twice daily dosage, and at 2100 on the study day for the once daily regimen. All subjects gave their informed consent and the study was approved by the Hospital Ethical Committee.

The study design was similar to that previously reported from our Department.¹ Patients were admitted to a specially allocated ward at 0730 having fasted from midnight. A 10 French gauge naso-

Address for correspondence: Dr R H Hunt, Department of Surgery, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.

Received for publication 18 February 1982

gastric Salem sump tube was passed and position checked by water aspiration. Patients ate identical meals at the same time on each study day and the number of cigarettes and drinks consumed was recorded and repeated on subsequent study days.

Throughout the study, a sample of gastric juice was taken hourly for estimation of pH using a glass electrode (Radiometer, Copenhagen) calibrated with buffers at pH 4 and 7 before each hourly batch of measurements. At 0100 the stomach was emptied and continuous aspiration applied overnight using a mechanical pump at -50 mm of Hg, interrupted by manual aspiration every 20 minutes. The hourly volume of gastric secretion was recorded, a 5 ml aliquot taken for titration to pH 7 with 0.1 N sodium hydroxide using an autoburette (Radiometer, Copenhagen) and acid output calculated.

For the purposes of statistical analysis, pH was converted to hydrogen ion activity (H⁺). Statistical comparison of H⁺ activity was performed using a Fisher's significant differences test (with p<0.05) which takes into account all possible comparisons between treatments. Analysis of nocturnal acid output on different treatments was performed using a Friedman rank sum multiple comparison procedure.

Results

INTRAGASTRIC ACIDITY

The results of the five treatments are shown in Fig. 1. 1. Twice daily ranitidine decreased mean 24 hour




Fig. 1 Mean 24 hour hydrogen ion activity ± SE for five treatments.




Fig. 2 Mean hourly H⁺ activity ± SE over 24 hour period after placebo, cimetidine 400 mg bd, and ranitidine 150 mg bd.

H⁺ activity by 63% (p<0.05), twice daily cimetidine by 30% (p<0.05), night time ranitidine by 62% (p<0.05), and night time cimetidine by 40% (p<0.05). Twice daily ranitidine was significantly better at reducing mean 24 h H⁺ activity than twice daily cimetidine (p<0.05) (Fig. 2) and night time ranitidine provided significantly better control of acidity than night time cimetidine (p<0.05) (Fig. 3). Cimetidine 800 mg was not significantly different




Fig. 3 Mean hourly H⁺ activity ± SE over the 24 hour period after placebo, cimetidine 800 mg nocte, and ranitidine 300 mg nocte.




Fig. 4 Mean nocturnal acid output \pm SE for five treatments.

from 400 mg bd and there was no significant difference between the two ranitidine treatments.

Reduction in H^+ activity during the morning (0900–1300) was 53% with twice daily cimetidine, 86% with twice daily ranitidine, 20% with night time cimetidine, and 50% with night time ranitidine. Although after lunch twice daily ranitidine reduced H^+ activity by 29% there was little reduction with the other treatments (Figs 2 and 3). Overnight, however, reductions were 34% with twice daily cimetidine, 54% with twice daily ranitidine, 56% with night time cimetidine, and 85% with night time ranitidine.

NOCTURNAL ACID OUTPUT

The results of the five treatments are shown in Figure 4. Cimetidine 400 mg bd decreased nocturnal acid output from 5.1 mmol/h to 3.7 mmol/h (NS), ranitidine 150 mg bd to 1.4 mmol/h ($p < 0.05$), cimetidine 800 mg nocte to 1.6 mmol/h ($p < 0.05$), and ranitidine 300 mg nocte to 0.8 mmol/h ($p < 0.05$). Night time cimetidine and the two regimens of ranitidine were all significantly more effective at decreasing acid output than cimetidine 400 mg bd. There was no significant difference between twice daily ranitidine, night time cimetidine, and night time ranitidine.

Discussion

Nocturnal acid output and 24 hour H^+ activity were controlled better by ranitidine 150 mg bd than by cimetidine 400 mg bd and although ranitidine 300

mg nocte was better than cimetidine 800 mg nocte at decreasing mean 24 hour intragastric acidity, there was no difference between these latter two treatments at decreasing nocturnal acid output. Although nocturnal acid output was controlled better by cimetidine 800 mg nocte than cimetidine 400 mg bd, there was no significant difference between ranitidine 300 mg nocte and ranitidine 150 mg bd. There was also no significant difference in decreasing 24 hour H^+ activity between the two ranitidine treatments or between the two cimetidine treatments.

Twice daily cimetidine was better than night time cimetidine at decreasing H^+ activity during the morning but there was little difference between these two treatments after lunch. Overnight, the large single night time dose of cimetidine had a much greater effect on acid output and H^+ activity compared with the twice daily dose of this drug. Although there was a difference in decreasing H^+ activity between twice daily ranitidine and night time ranitidine during the morning, this was not as marked after lunch, and overnight, night time ranitidine was much better than twice daily ranitidine. Thus a single large nocturnal dose of an H_2 receptor antagonist is at least as effective at controlling both 24 hour H^+ activity and nocturnal acid output than a twice daily regimen.

Our results confirm our previous observation that twice daily doses of ranitidine¹³ and cimetidine¹⁴ are effective at decreasing 24 hour intragastric acidity although the decrease is not as great as our previous reports. This was probably because in the present study, half of the patients met our criteria of poor clinical response to cimetidine.¹² These patients had ultimately healed their ulcers with a variety of medical treatments other than H_2 receptor blockade. The previous poor response to cimetidine may also explain why the twice daily regimen of cimetidine had a decreased effect on H^+ activity and acid output in contrast with the twice daily ranitidine dosage. There have been three previous reports of ranitidine healing cimetidine resistant ulcers^{15–17} but these were not controlled studies.

Blackwood and Northfield¹⁸ showed that although cimetidine 800 mg had an increased and more prolonged effect on intragastric pH than the 400 mg dose both these regimens inhibit nocturnal acid output by a similar degree (92.7% and 94.2% respectively). This degree of acid inhibition is much greater than our report in patients showing a poor clinical response to treatment¹⁹ when we failed to observe a significantly greater effect after increasing the dose of cimetidine from 1 g/day to 2 g/day.

Maintenance therapy with cimetidine 800 mg nocte has been shown to have a lower relapse rate²⁰

than with the 400 mg dose¹⁷ and Fitzpatrick *et al* have suggested that maintenance therapy with cimetidine 400 mg nocte has mainly an antacid effect whereas cimetidine 800 mg nocte results in a real reduction of relapse rate.²¹

Cimetidine and ranitidine may increase serum prolactin^{22 23} and by using a large nocturnal dose the risk of prolactin release might be increased in some patients. A total daily dose of cimetidine 800 mg nocte, however, is less than the 1 g/day originally recommended for cimetidine¹ and while using an 800 mg nocte dose for maintenance therapy, Blackwood *et al* reported no adverse events.²⁰ In addition, Burland *et al*²⁴ found no increase in serum prolactin after an 800 mg dose of cimetidine in healthy subjects.

On placebo, H⁺ activity was lower during the daytime than during the overnight period which is when patients classically complain of pain relieved by food. Food buffering is more physiological than pharmacological control of acid secretion and the morning dose of an H₂ receptor antagonist may therefore be unnecessary.

If the concept of 'no acid no ulcer' is correct,²⁵ using a large single nocturnal dose of either cimetidine or ranitidine provides practical as well as theoretical advantages; patients would find a single dose more convenient and acceptable and compliance is likely to be better. Our study has shown that a single night time dose of an H₂ receptor antagonist is as effective as a twice daily regimen of these drugs in reducing H⁺ activity and acid output and we suggest that a large single nocturnal dose of treatment be evaluated by clinical trial.

References

- 1 Pounder RE, Williams JG, Milton-Thompson GJ, Misiewicz JJ. Effect of cimetidine on 24 hour intragastric acidity in normal subjects. *Gut* 1976; **17**: 133-8.
- 2 Burland WL, Brunet PL, Hunt RH, Melvin MA, Mills JG, Vincent D, Milton-Thompson GJ. Comparison of the effects on intragastric acidity of SK&F 92994 and two dose regimens of cimetidine. *Hepato-Gastroenterology Suppl.* 1980; E32: **10**: 259.
- 3 Kerr GD. Cimetidine: twice daily administration in duodenal ulcer - results of a UK and Ireland multicentre study. In: Baron JH, ed. *Cimetidine in the 80's*. Edinburgh: Churchill Livingstone, 1981: 9-13.
- 4 Eckardt V. Cimetidine: twice daily administration in duodenal ulcer - results of a European multicentre study. In: Baron JH, ed. *Cimetidine in the 80's*. Edinburgh: Churchill Livingstone, 1981: 14-20.
- 5 Langman MJS, Henry DA, Ogilvie A. Ranitidine and cimetidine for duodenal ulcer. *Scand J Gastroenterol* 1981; **16 Suppl 69**: 115-7.
- 6 Walt RP, Trotman IF, Frost R *et al*. Comparison of twice daily ranitidine with standard cimetidine treatment of duodenal ulcer. *Gut* 1981; **22**: 319-22.
- 7 Burland WL, Hawkins BW, Beresford J. Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study. *Postgrad Med J* 1980; **56**: 173-6.
- 8 Boyd EJS, Wilson JA, Wormsley KG. Failure of maintenance therapy in duodenal ulcer. *Gut* 1980; **21**: 455.
- 9 Hunt RH, Vincent D, Kelly JM, Perry M, Milton-Thompson GJ. Comparison of medical and surgical reduction in intragastric acidity in duodenal ulcer. *Gut* 1980; **21**: 455.
- 10 Peterson WL, Sturdevant RAL, Franki HD *et al*. Healing of duodenal ulcer with an antacid regimen. *N Engl J Med* 1977; **2197**: 341-5.
- 11 Dragstedt LR, Owens FM. Supradiaphragmatic section of the vagus nerves in treatment of duodenal ulcer. *Proc Soc Exp Biol (NY)* 1943; **53**: 152-4.
- 12 Hunt RH. Non-responders to cimetidine treatment, Part 1. In: Baron JH, ed. *Cimetidine in the 80's*. Edinburgh: Churchill Livingstone, 1981: 34-41.
- 13 Walt RP, Male PJ, Rawlings J, Hunt RH, Milton-Thompson GJ, Misiewicz JJ. Comparison of the effects of ranitidine, cimetidine and nocturnal acid secretion in patients with duodenal ulcer. *Gut* 1981; **22**: 40-54.
- 14 Gledhill T, Mills JG, Clancy A, Buck M, Hunt RH, Burland WL. Nocturnal acid output and 24 hour intragastric acidity in duodenal ulcer patients are significantly inhibited by an evening dose of SK&F 93479. *Gut* 1982; **23**: A455.
- 15 Mohammed R, Mitchell KG, MacKay C. The treatment of cimetidine resistant peptic ulcers by ranitidine hydrochloride: a new H₂ receptor antagonist. *Curr Med Pres Opin* 1981; **7**: 523-5.
- 16 Brunner G. Cimetidine-resistant ulcers. In: *The clinical use of ranitidine*. Glaxo International Symposium Medicine International Review 1982. Oxford: Medical Education Service Ltd, 1982: 19.
- 17 Schutz E. Benandlung cimetidin resistenten ulcera duodeni mit den neuer H₂ rezeptor-antagonisten ranitidin. *Therapiewoche* 1982; **32**: 2077-8.
- 18 Blackwood WS, Northfield TC. Nocturnal gastric acid secretion: effect of cimetidine and interaction with anticholinergics. In: *Proceedings of the second international symposium on histamine H₂ receptor antagonists*. Amsterdam: Excerpta Medica, 1977: 124-30.
- 19 Gledhill T, Buck M, Paul A, McEwen J, Hunt RH. The effect of cimetidine 1 g/day and cimetidine 2 g/day on 24 hour intragastric acidity and nocturnal acid secretion in cimetidine non-responders. *Gut* 1982; **23**: A454.
- 20 Blackwood WS, Maudgal DP, Northfield TC. Prevention by bedtime cimetidine of duodenal ulcer relapse. *Lancet* 1978; **1**: 626-7.
- 21 Fitzpatrick WJ, Blackwood WS, Northfield TC. Bedtime cimetidine maintenance treatment: optimum dose and effect on subsequent natural history of duodenal ulcer. *Gut* 1982; **23**: 239-42.
- 22 Knigge U, Wollesen F, Dejgarrd A, Thuesen B, Christiansen PM. Comparison between dose-response

- of prolactin. Thyroid stimulating hormone and growth hormone to two different histamine H₂ receptor antagonists in normal men. *Clin Endocrinol* 1981; **15**: 585-92.
- 23 Lombardo L. Reversible amenorrhoea after ranitidine treatment. *Lancet* 1982; **1**: 224.
- 24 Burland WL, Gleadle RI, Lee RM, Rowley-Jones D, Groom GV. Prolactin response to cimetidine. *Br J Clin Pharmacol* 1979; **7**: 19-21.
- 25 Schwartz K. Ueber penetrierende magen - und jejunalgeschure. *Bruns Beitr Klin Chir* 1910; **67**: 96-128.